New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1) -

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)
Information type: Randomised controlled trials
Source: Diabetes Care
Specialities: Diabetes
Summary
This study found insulin glargine 300 units/mL (a new formulation) resulted in HbA1c reductions that were equivalent to those seen with glargine 100 units/mL (Lantus®), but with fewer episodes of nocturnal hypoglycaemia (severe events in 36 vs. 46%; P<0.005).
UKMi comment
Insulin glargine U300 (Toujeo®) is a new formulation based on the insulin glargine molecule, but with a reduced redissolution rate following subcutaneous administration, resulting in a flatter and more prolonged pharmacokinetic/dynamic profile than Lantus®. According to the UKMi New Drugs Online database, insulin glargine U300 is likely to be launched around the same time that Lantus® loses patent protection in late 2014.
Related links: